This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Apellis Pharmaceuticals (APLS) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of 0% and 7.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
Apellis' (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Apellis Pharmaceuticals, Inc. (APLS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
by Zacks Equity Research
HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte are part of the Zacks top Analyst Blog.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -10.61% and 0.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical (DERM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
5 Stocks to Buy That Are Poised to Beat on Earnings This Week
by Nalak Das
We have narrowed our search to five stocks that are poised to beat on earnings this week. These are: HEi, CEG, IPAR, APLS, PCVX.
Viatris (VTRS) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q4 results are likely to gain from momentum in its branded and generic businesses.
Why Apellis (APLS) Might Surprise This Earnings Season
by Zacks Equity Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Apellis Pharmaceuticals, Inc. (APLS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan
by Zacks Equity Research
Apellis (APLS) stock falls on the CHMP's negative recommendation to the EMA regarding the approval of intravitreal pegcetacoplan in the EU for the treatment of geographic atrophy secondary to age-related macular degeneration.
Annexon (ANNX) Stock Rallies 156% in 3 Months: Here's How
by Zacks Equity Research
Annexon (ANNX) has rallied 156% in the past three months on plans to begin a registrational program for ANX007 in GA after reaching FDA alignment on the study's primary endpoint.
Apellis (APLS): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Apellis (APLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues
by Zacks Equity Research
Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.
Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA
by Zacks Equity Research
The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.